August 17th, 2016

To Whom It May Concern,

The Ohio Department of Medicaid (ODM) is pleased to announce the start of the Annual Preferred Drug List (PDL) review for the Medicaid fee-for-service (FFS) program. The Ohio Department of Medicaid’s Pharmacy and Therapeutics (P&T) Committee will conduct the annual PDL review on October 5, 2016.

Supplemental rebate bid submissions will be managed in a manner different from previous years. For the fiscal year beginning January 1, 2017, the supplemental rebate program for the Ohio Medicaid FFS program will be facilitated through the Sovereign State Drug Consortium (SSDC). ODM requests that all supplemental rebate offers for the Ohio Medicaid FFS program be directed to SSDC. Additional information regarding SSDC is available at www.rxssdc.org.

Similar to past years preferred drugs will be selected during the annual PDL review. These decisions will be made by the ODM based upon the recommendations made by the P&T Committee. The following drug classes are subject to review at the annual meeting:

**Analgesic Agents: NSAIDs†**  
Analgesic Agents: Gout  
Analgesic Agents: Opioids  
Blood Formation, Coagulation, and Thrombosis Agents: Hematopoietic Agents  
Blood Formation, Coagulation, and Thrombosis Agents: Heparin-Related Preparations  
Blood Formation, Coagulation, and Thrombosis Agents: Oral Anticoagulants  
Cardiovascular Agents: Angina, Hypertension & Heart Failure  
Cardiovascular Agents: Antiarrhythmics  
Cardiovascular Agents: Lipotropics  
Cardiovascular Agents: Pulmonary Arterial Hypertension  
Central Nervous System (CNS) Agents: Alzheimer’s Agents  
Central Nervous System (CNS) Agents: Anti-Migraine Agents  
Central Nervous System (CNS) Agents: Anticonvulsants  
Central Nervous System (CNS) Agents: Antidepressants  
Central Nervous System (CNS) Agents: Antipsychotics, Second Generation  
Central Nervous System (CNS) Agents: Attention Deficit Hyperactivity Disorder Agents  
Central Nervous System (CNS) Agents: Fibromyalgia Agents  
Central Nervous System (CNS) Agents: Medication Assisted Treatment of Opioid Addiction  
Central Nervous System (CNS) Agents: Multiple Sclerosis  
Central Nervous System (CNS) Agents: Neuropathic Pain  
Central Nervous System (CNS) Agents: Parkinson’s Agents  
Central Nervous System (CNS) Agents: Restless Legs Syndrome  
Central Nervous System (CNS) Agents: Sedative-Hypnotics, Non-Barbiturate  
Central Nervous System (CNS) Agents: Skeletal Muscle Relaxants, Non-Benzodiazepine  
Central Nervous System (CNS) Agents: Smoking Deterrents  
Endocrine Agents: Diabetes Adjunctive Therapy  
Endocrine Agents: Diabetes – Insulin  
Endocrine Agents: Diabetes – Oral Hypoglycemics
Endocrine Agents: Estrogenic Agents
Endocrine Agents: Growth Hormone
Endocrine Agents: Osteoporosis – Bone Ossification Enhancers
Gastrointestinal Agents: Anti-Emetics
Gastrointestinal Agents: IBS/ SBS/ Selected GI Agents†
Gastrointestinal Agents: Pancreatic Enzymes
Gastrointestinal Agents: Proton Pump Inhibitors
Gastrointestinal Agents: Ulcerative Colitis Agents
Genitourinary Agents: Benign Prostatic Hyperplasia
Genitourinary Agents: Electrolyte Depleter Agents
Genitourinary Agents: Urinary Antispasmodics
Immunomodulator Agents for Systemic Inflammatory Disease
Infectious Disease Agents: Antibiotics – Cephalosporins
Infectious Disease Agents: Antibiotics – Macrolides
Infectious Disease Agents: Antibiotics – Quinolones
Infectious Disease Agents: Antibiotics – Inhaled
Infectious Disease Agents: Antifungals for Onychomycosis & Systemic Infections
Infectious Disease Agents: Antivirals – Hepatitis C Agents
Infectious Disease Agents: Antivirals – Herpes
Infectious Disease Agents: Antivirals – HIV
Ophthalmic Agents: Antibiotic and Antibiotic-Steroid Combination Drops and Ointments
Ophthalmic Agents: AntiHistamines & Mast Cell Stabilizers
Ophthalmic Agents: Glaucoma Agents
Ophthalmic Agents: NSAIDs
Otic Agents: Antibacterial and Antibacterial/Steroid Combinations
Respiratory Agents: Antihistamines – Second Generation
Respiratory Agents: Beta-Adrenergic Agonists – Inhaled, Short Acting
Respiratory Agents: Beta-Adrenergic Agonists – Inhaled, Long Acting
Respiratory Agents: Chronic Obstructive Pulmonary Disease
Respiratory Agents: Epinephrine Auto-Injectors
Respiratory Agents: Glucocorticoid Agents – Inhaled
Respiratory Agents: Hereditary Angioedema
Respiratory Agents: Leukotriene Receptor Modifiers and Inhibitors
Respiratory Agents: Nasal Preparations
Topical Agents: Acne Preparations
Topical Agents: Androgens
Topical Agents: Anti-Fungals
Topical Agents: Anti-Parasitics
Topical Agents: Corticosteroids
Topical Agents: Immunomodulators

†Category represent new or expanded categories for the PDL. A complete list of drugs under these categories is available at the end of this document.

Manufacturers may request to present clinical information at sessions to be held the morning of October 5, 2016 by emailing PBA_OHMedicaidFFS@changehealthcare.com no later than August 31, 2016. Manufacturers may be requested to fill out an intent to present form once they have identified an interest in presenting. Times for presentations will be finalized after all requests have been received.

Thank you for your participation
<table>
<thead>
<tr>
<th>PDL NEW CLASSES</th>
<th>IBS/ SBS AGENTS/ SELECTED GI</th>
<th>NSAIDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>alosetron (Lotronex®)</td>
<td>bisacodyl (Dulcolax®)</td>
<td>celecoxib (Celebrex®)</td>
</tr>
<tr>
<td>dicyclomine (Bentyl®)</td>
<td>casanthranol/docusate sodium</td>
<td>diclofenac</td>
</tr>
<tr>
<td>linaclotide (Linzess®)</td>
<td>lactulose (Chronulac®)</td>
<td>diclofenac/misoprostol (Arthrotec®)</td>
</tr>
<tr>
<td>eluxadoline (Viberzi®)</td>
<td>polyethylene glycol 3350 (Miralax®)</td>
<td>diclofenac potassium (Zipsor®)</td>
</tr>
<tr>
<td>lubiprostone (Amitiza®)</td>
<td>psyllium (various brand names)</td>
<td>diclofenac (Zorvolex®)</td>
</tr>
<tr>
<td>Methylnaltrexone (Relistor®)</td>
<td>senna (Senokot®)</td>
<td>etodolac</td>
</tr>
<tr>
<td>naloxEGOL (Movantik®)</td>
<td></td>
<td>fenoprofen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ibuprofen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ibuprofen/famotidine (Duexis®)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>indomethacin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>indomethacin (Tivorbex®)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ketoprofen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ketorolac</td>
</tr>
<tr>
<td></td>
<td></td>
<td>meclofenamate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>mefenamic acid</td>
</tr>
<tr>
<td></td>
<td></td>
<td>meloxicam</td>
</tr>
<tr>
<td></td>
<td></td>
<td>meloxicam (Vivlodex™)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>nabumetone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>naproxen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>naproxen/esomeprazole (Vimovo®)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>oxaprozin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>piroxicam</td>
</tr>
<tr>
<td></td>
<td></td>
<td>sulindac</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tolmetin</td>
</tr>
</tbody>
</table>